Abstract
Identification, monitoring, and, more importantly, linkage of critical quality attributes (CQAs) in processing parameters in a biopharmaceutical product is required to ensure the quality and manufacturing consistency of the product, but also its safety and efficacy during clinical and commercial development. Recently, bottom-up and middle-up liquid chromatography–mass spectrometry (LC–MS) characterization strategies using immobilized enzyme reactors (IMERs) in combination with multidimensional liquid chromatography coupled with high-resolution MS (MDLC–HRMS), as well as sophisticated software solutions, have been added to the analytical toolbox. These strategies not only allow faster characterization of post-translational modifications (PTMs) present in biotherapeutic proteins but also have the potential to provide a fully automated and unified bottom-up, middle-up, and intact LC–MS characterization approach.
Publisher
Multimedia Pharma Sciences, LLC
Reference19 articles.
1. D.E. Johnson, Int. J. Mol. Sci. 19, 11 (2018). DOI: 10.3390/ijms19113685.
2. X. Zhong and A.M. D’Antona, Antibodies (Basel) 10, 2 (2021). DOI: 10.3390/antib10020013.
3. A. Rathore and H. Winkle, Nat. Biotechnol. 27(1), 26–34 (2009). DOI: 10.1038/nbt0109-26.
4. International Conference on Harmonization, ICH Q8(R2), Pharmaceutical Development (ICH, Geneva, Switzerland, 2009).
5. X. Xu, et al, PLoS One 14(10), e0223899 (2019). DOI: 10.1371/journal.pone.0223899.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献